Cingulate Inc
NASDAQ:CING
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mirriad Advertising PLC
LSE:MIRI
|
UK |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (14.4), the stock would be worth $-22.61 (515% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.5 | $5.45 |
0%
|
| Industry Average | 14.4 | $-22.61 |
-515%
|
| Country Average | 16.7 | $-26.19 |
-581%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Cingulate Inc
NASDAQ:CING
|
63.4m USD | -3.5 | -2.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 53.7 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 23.6 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 22.5 | 30 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 19.5 | 15.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF | 15.7 | 20.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 10.3 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 17.5 | 20.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 10.7 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Cingulate Inc
Glance View
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).
